Cambridge Cognition - COG Share Forecast, Price & News

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online trial recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases I-IV; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; CANTAB Insight, a medical device that helps to determine an individual's cognitive health; and NeuroVocalix for an automated administration and scoring of well-validated verbal cognitive assessments?on a secure platform. In addition, the company offers a range of expert consultancy and operational management services to optimize clinical trials and cognitive research, which include neuroscience and technical consultancy, study design, data analysis, study and data management, and reports and interpretation. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.

Cambridge Cognition Stock Performance

Shares of COG Stock traded down GBX 1.25 ($0.02) during trading on Monday, reaching GBX 130.25 ($1.60). 2,035 shares of the company's stock were exchanged, compared to its average volume of 47,193. The company has a quick ratio of 0.87, a current ratio of 1.01 and a debt-to-equity ratio of 2.85. The firm's fifty day moving average price is GBX 123.07 and its 200-day moving average price is GBX 132.97. Cambridge Cognition has a twelve month low of GBX 98.80 ($1.21) and a twelve month high of GBX 189.88 ($2.33). The stock has a market capitalization of £40.60 million and a PE ratio of 13,025.00.

Insider Buying and Selling at Cambridge Cognition

In related news, insider Matthew Stork bought 22,950 shares of Cambridge Cognition stock in a transaction that occurred on Thursday, July 21st. The stock was acquired at an average price of GBX 113 ($1.38) per share, with a total value of £25,933.50 ($31,777.36).